CGON
CG Oncology, Inc.
68.80$
-6.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 130,388.9% | 400.0% | 0.8% | 16,639.6% | 45,632.6% | 5,877.2% | 52,821.2% | – | 94.7% | 125.5% | 273.5% | 339.2% | 182.7% | |
| -130,288.9% | -300.0% | 99.2% | -16,539.6% | -45,532.6% | -5,777.2% | -52,721.2% | – | 5.3% | -25.5% | -173.5% | -239.2% | -82.7% | |
| 130,388.9% | 1,591,500.0% | 3,253.3% | 16,639.6% | 45,632.6% | 5,877.2% | 52,821.2% | – | 1,673.7% | 1,290.2% | 4,037.9% | 4,724.0% | 2,508.5% | |
| 25,744.4% | 301,800.0% | 1,094.1% | 6,751.4% | 20,269.8% | 2,566.9% | 28,440.4% | – | 1,400.6% | 774.9% | 1,918.7% | 2,504.4% | 1,462.5% | |
| 25,744.4% | 1,892,900.0% | 4,346.7% | 6,751.4% | 20,269.8% | 2,566.9% | 28,440.4% | – | 3,074.3% | 2,071.8% | 5,956.6% | 7,228.4% | 3,973.5% | |
| -156,033.3% | -1,893,200.0% | -4,247.4% | -23,291.0% | -65,802.3% | -8,344.1% | -81,161.5% | – | -3,069.0% | -2,097.3% | -6,130.1% | -7,467.7% | -4,056.2% | |
| -130,755.6% | -1,611,600.0% | -3,200.8% | -17,028.8% | -47,453.5% | -6,973.2% | -66,253.8% | – | -2,629.5% | -1,779.0% | -5,558.8% | -6,832.8% | -3,602.7% | |
| -25,188.9% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -130,755.6% | -1,611,600.0% | -3,200.8% | -17,028.8% | -47,453.5% | -6,973.2% | -66,253.8% | – | -2,629.5% | -1,779.0% | -5,558.8% | -6,832.8% | -3,602.7% | |
| -130,707.4% | -1,611,200.0% | -3,200.0% | -17,022.5% | -47,404.7% | -6,973.2% | -66,207.7% | – | -2,604.6% | -1,742.5% | -5,481.2% | -6,832.8% | -3,568.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.